natgillin/translations-raw huggingface dataset:
Travoprost has harmful pharmacological effects on pregnancy and/or the foetus/new-born child.
Travoprostil on kahjulik farmakoloogiline toime rasedusele ja/või lootele/vastsündinule.
Travoprost is a prostaglandin analogue (a man-made copy of the natural substance prostaglandin) that works by increasing the drainage of fluid out of the eye.
Travoprost on prostaglandiini analoog (loodusliku aine prostaglandiini sünteetiline variant), mis suurendab vedeliku väljavoolu silmast.
Travoprost is a prostaglandin analogue which works by increasing the outflow of liquid of the eye, which lowers its pressure.
Travoprost on prostaglandiini analoog, mille mõjul suureneb vedeliku väljavool silmast ja silmasisene rõhk langeb.
Travoprost may be absorbed through the skin.
Travoprost võib imenduda läbi naha.
Travoprost may gradually change eyelashes in the treated eye(s); these changes were observed in about half of the patients in clinical trials and include: increased length, thickness, pigmentation, and/or number of lashes.
Travoprost võib ravitud silmas (silmades) esile kutsuda muutusi ripsmetes; neid muutusi leiti umbes pooltel kliinilistes uuringutes osalenud patsientidel ja nende hulka kuuluvad: suurenenud pikkus, paksus, pigmentatsioon ja/või ripsmete arv.
Travoprost may gradually change the eye colour by increasing the number of melanosomes (pigment granules) in melanocytes.
Travoprost võib põhjustada järk-järgulist silmavärvi muutumist, kuna suurendab melanosoomide (pigmendigraanulite) hulka melanotsüütides.
Travoprost must not be used in women of child bearing age/potential unless adequate contraceptive measures are in place (see section 5.3).
Travoprosti ei tohi kasutada fertiilses eas naised (võimelised rasestuma) ilma vastavaid rasestumisvastaseid vahendeid kasutamata (vt lõik 5.3).
Travoprost on its own has been authorised in the European Union as Travatan since 2001.
Travoprost on ravimina Travatan Euroopa Liidus heaks kiidetud alates 2001. aastast.
Travoprost significantly increased optic nerve head blood flow in rabbits following 7 days of topical ocular administration (1.4 micrograms, once-daily).
Travoprost suurendas märkimisväärselt nägemisnärvi pea verevoolu pärast ravimi 7-päevast toopilist silma manustamist küülikutele (1,4 mikrogrammi üks kord päevas).
Travoprost, a prostaglandin F2 analogue, is a full agonist which is highly selective and has a high affinity for the prostaglandin FP receptor, and reduces the intraocular pressure by increasing the outflow of aqueous humour via trabecular meshwork and uveoscleral pathways.
Travoprost on prostaglandiin F2 analoog, täielik agonist, mis on kõrge selektiivsusega ja suure afiinsusega prostaglandiin FP retseptori suhtes ja langetab silmasisest rõhku, suurendades vesivedeliku väljavoolu trabekulaarvõrgustiku ja uveoskleraalsete kanalite kaudu.
TRAY BACKING TEXT
Blisterpakend
TRAY FOR PRE-FILLED SYRINGE
SÜSTLI ALUS
TRAY FOR PRE-FILLED SYRINGE WITH NEEDLE GUARD
NÕELAKAITSEGA SÜSTLI ALUS
TRAY TOP LID LABEL FOR 12 MG PACK
ALUSE PEALMISE KATTE MÄRGISTUS, 12 MG PAKEND
TRAY TOP LID LABEL FOR 4 MG PACK
ALUSE PEALMISE KATTE MÄRGISTUS, 4 MG PAKEND
TRAY UNDERSIDE OF LID STICKER FOR 12 MG PACK
ALUSE KATTE KLEEBISE ALUMINE KÜLG, 12 MG PAKEND
TRAY UNDERSIDE OF LID STICKER FOR 4 MG PACK
ALUSE KATTE KLEEBISE ALUMINE KÜLG, 4 MG PAKEND
TRAZEC 120 mg film-coated tablets
TRAZEC 120 mg õhukese polümeerikilega kaetud tabletid
Trazec 120 mg film-coated tablets are yellow, ovaloid tablets with “NVR” marked on one side and “TSL” on the other.
Trazec 120 mg õhukese polümeerikilega kaetud tabletid on kollast värvi, ovaalsed, tähistusega “NVR” ühel ja “TSL” teisel küljel.
TRAZEC 180 mg film-coated tablets
TRAZEC 180 mg õhukese polümeerikilega kaetud tabletid
Trazec 180 mg film-coated tablets are red, ovaloid tablets with “NVR” marked on one side and “TSX” on the other.
Trazec 180 mg õhukese polümeerikilega kaetud tabletid on punast värvi, ovaalsed, tähistusega “NVR” ühel ja “TSX” teisel küljel.
TRAZEC 60 mg film-coated tablets
TRAZEC 60 mg õhukese polümeerikilega kaetud tabletid
Trazec 60 mg film-coated tablets are pink, round tablets with “NVR” marked on one side and “TS” on the other.
Trazec 60 mg õhukese polümeerikilega kaetud tabletid on roosat värvi, ümmargused, tähistusega “NVR” ühel ja “TS” teisel küljel.
Trazec and older people
Trazec ja eakad inimesed
Trazec can be used by people over 65 years of age.
Trazec’it võivad kasutada ka üle 65-aastased inimesed.
Trazec is a medicine to lower blood sugar (glucose), which is taken by mouth (these medicines are also known as oral anti-diabetics).
Trazec on ravim veresuhkru (glükoosi-) taseme alandamiseks, mida võetakse suu kaudu (taolisi ravimeid tuntakse ka kui suukaudseid diabeedivastaseid ravimeid).
Trazec is given within one to 30 minutes before breakfast, lunch and dinner and the dose is adjusted to give the best control.
Trazecit manustatakse 1–30 minutit enne hommiku-, lõuna- ja õhtusööki, kusjuures annust kohandatakse nii, et tulemus oleks võimalikult parim.
Trazec is not recommended for children and adolescents (under 18 years of age) because its effects in this age group have not been studied.
Trazec’it ei soovitata kasutada lastel ja noorukitel (vanuses alla 18 aasta), sest ravimi toimeid ei ole selles vanuserühmas uuritud.
Trazec is used together with metformin (another antidiabetes medicine) to lower blood glucose (sugar) in patients whose diabetes cannot be controlled by metformin alone.
Trazecit kasutatakse koos metformiiniga (samuti diabeedi ravim), et alandada glükoosi (suhkru) sisaldust veres nendel patsientidel, kelle diabeeti pole võimalik ainuüksi metformiiniga kontrolli all hoida.
Trazec tablets contain lactose monohydrate.
Trazec’i tablett sisaldab laktoosmonohüdraati.
Trazec tablets start to act quickly after you take them and are eliminated from the body rapidly.
Trazec’i tabletid hakkavad toimima kiiresti pärast sissevõtmist, samuti erituvad organismist kiiresti.
Trazec works by stimulating the pancreas to produce insulin more quickly.
Trazec’i toime stimuleerib pankreast tootma insuliini kiiremini.
Trazec, like other oral antidiabetic agents, is not recommended for use in pregnancy.
Sarnaselt teiste suukaudsete diabeedivastaste ravimitega ei soovitata Trazec’it raseduse ajal kasutada.
Trazodone
Kolhitsiin
trazodone
Trazodoon
Trazodone
Tritsüklilised
Trazodone (a medicine for depression) as, unwanted effects like nausea, dizziness, low blood pressure and fainting can occur when taken with Norvir.
Trasodoon (depressiooniravim), sest kõrvaltoimed nagu iiveldus, peapööritus, madal vererõhk ja minestamine võivad tekkida, kui ravimit manustatakse koos Norvir’iga.
trazodone (used to treat depression)
trasodoon (kasutatakse depressiooni raviks);
Trazodone 50 mg SD Ritonavir 200 mg BID
Trasodoon 50 mg SD Ritonaviir 200 mg BID
trazodone exposure.
trasodooni ekspositsiooni tõusu.
trazodone should be considered.
kaaluda tuleb trasodooni
Trazodone single dose
Trasodooni üksikannus
trazodone, a medicine used to treat depression
trasodoon – ravim, mida kasutatakse depressiooni raviks;
trazodone, a medicine used to treat depression
trasodoon, ravim, mida kasutatakse depressiooni raviks;
Trazodone:
Trasodoon:
Trazodone: AUC: ↑ 2.4-fold
AUC: ↑ 2,4 korda
Trazodone: AUC: ↑ 2.4-fold
koosmanustamisel
Treat all Imlygic spills with a virucidal agent and absorbent materials.
Kõik Imlygic’u pritsmed tuleb puhastada viirusvastase aine ja absorbendiga.
Treat bacterial infections (e.g. clarithromycin, doxycycline)
ravivad bakteriaalseid nakkusi (nt klaritromütsiin, doksütsükliin)
treat blood clots in the veins of the legs (deep vein thrombosis) and in the blood vessels in the lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels in the legs and/or lungs.
et ravida verehüübeid jalaveenides (süvaveenitromboos) ja kopsuveresoontes (kopsuarteri trombemboolia) ning ennetamaks verehüüvete taasteket jalgade ja/või kopsude veresoontes.
Treat cancer (e.g. cabazitaxel)
ravivad vähki (nt kabasitakseel)
Treat certain psychiatric disorders such as severe anxiety or schizophrenia (e.g. diazepam, midazolam, haloperidol)
ravivad teatud psühhiaatrilisi häireid, nt raskekujulist ärevushäiret või skisofreeniat (nt diasepaam, midasolaam, haloperidool)
Treat epilepsy (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid)
ravivad epilepsiat (nt karbamasepiin, klonasepaam, fenütoiin, primidoon, valproehape)
Treat heart conditions or lower blood pressure (e.g. bisoprolol, digoxin, diltiazem, felodipine, nicardipine, nifedipine, propranolol, verapamil)
ravivad südamehaigusi või alandavad vererõhku (nt bisoprolool, digoksiin, diltiaseem, felodipiin, nikardipiin, nifedipiin, propranolool, verapamiil)
Treat pain (e.g. fentanyl, tramadol)
vaigistavad valu (nt fentanüül, tramadool)
treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products.
sekundaarse hüperparatüreoidismi ravi raske neeruhaigusega patsientidel, kes vajavad dialüüsi, et puhastada verd jääkainetest.
Treat sleep disorders (e.g. zolpidem)
ravivad unehäireid (nt zolpideem)
treat some types of heart attack and severe angina (pain caused by narrowing of the arteries in the heart). treat blood clots in blood vessels that are near the surface of the skin of the legs (superficial- vein thrombosis).
teatud tüüpi südamelihase infarkti ja raskekujulise stenokardia (valu, mida põhjustab südame pärgarterite ahenemine). verehüüvete raviks veresoontes, mis on jalgadel nahapinna läheduses (pindmiste veenide tromboos)
Treat thyroid disorders (e.g. levothyroxine)
ravivad kilpnäärme häireid (nt levotüroksiin)
Treat with Day 8 dose level and follow with WBC Growth Factors
Ravida 8. päeva annuse tasemega ja manustada seejärel vere valgeliblede kasvufaktoreid
Treat with insulin or oral hypoglycaemic agents as needed
Ravida vajaduse korral insuliini või suukaudsete vere glükoosisisaldust vähendavate ravimitega.
Treat your pen with care.
Peate oma pensüstli käsitsemisel olema hoolikas.
Treated animals must not be handled for at least eight hours after application of the product.
Ravitud loomi ei tohi puudutada vähemalt 8 tundi pärast preparaadi manustamist.
Treated animals should not be allowed to sleep with their owners, especially children, on the day of treatment.
Ravimise päeval ei tohi ravitud loomadel lubada omanike, eriti laste juures magada.
Treated animals should not be allowed to sleep with their owners, especially children, on the day of treatment.
Ravipäeval ei tohi ravitud loomadel lubada omanike, eriti laste juures magada.
Treated dogs should not be allowed to enter surface water for 48 hours after treatment to avoid adverse effects on aquatic organisms. (See section 6.6)
Ravitud koeri ei tohi lubada 48 tunni vältel pärast ravi veekogudesse, et ära hoida kahjulik toime veeorganismidele (vt lõik 6.6).
Treated dogs should not be permitted to sleep with their owners, especially children, on the day of treatment.
Ravimise päeval ei tohi ravitud koertel lubada magada koos nende peremeestega, eriti koos lastega.
Treated dogs should therefore still be kept away from bitches on heat within the first 6 weeks after initial treatment
Seega tuleb ravitud koerad esimese 6 nädala jooksul alates ravi algusest indlevatest emastest koertest eemal hoida.
Treated dogs should therefore still be kept away from bitches on heat within the first 6 weeks after initial treatment.
Seega tuleb ravitud koerad esimese kuue nädala jooksul alates ravi algusest indlevatest emastest koertest eemal hoida.
Treated dogs should therefore still be kept away from bitches on heat within the first 8 weeks after initial treatment.
Seega tuleb ravitud koerad esimese kuue nädala jooksul alates ravi algusest indlevatest emastest koertest eemal hoida.
Treated ferrets should therefore still be kept away from jills on heat within the first weeks after initial treatment.
Seega tuleb ravitud tuhkrud esimese viie nädala jooksul alates ravi algusest indlevatest emastest tuhkrutest eemal hoida.
Treated Patients
Ravitud patsientide arv
Treated patients had a median age of 50 years (range: 18 to 67); 79% of patients were white; 13% were black/African-American; 1% were Asian; 9% were Hispanic or Latino.
Ravitud patsientide mediaanvanus oli 50 aastat (vahemik: 18 kuni 67); 79% patsientidest oli valgest rassist, 13% olid mustanahalised/afroameeriklased, 1% asiaadid, 9% hispaanlased või latiinod.
Treated patients N
Ravitud patsientide arv
Treated subjects (n = 201) had a median age of 56 years (range: 24 to 70); 70% of the subjects were male; 87% were White; 3% were Black; 9% were Hispanic or Latino; mean body mass index was 29 kg/m2 (range: 19 to 44 kg/m2); 73% had baseline HCV RNA levels greater than 6 log10 IU/mL; 34% had cirrhosis; 63% had HCV genotype 3; 75% were prior relapsers.
Ravitud osalejate (n = 201) vanuse mediaan oli 56 eluaastat (vahemikus 24...70); 70% osalejaist olid meessoost; 87% valgenahalised, 3% mustanahalised, 9% Hispaania või ladina päritolu; keskmine kehamassi indeks oli 29 kg/m2 (vahemikus 19...44 kg/m2); 73%-l oli ravieelne HCV RNA suurem kui 6 log10 RÜ/ml; 34%-l oli tsirroos; 63%-l oli HCV 3. genotüüp; 75%-l olid eelnevad retsidiivid.
Treated subjects (n = 278) had a median age of 54 years (range: 21 to 75); 54% of the subjects were male; 91% were White; 5% were Black; 11% were Hispanic or Latino; mean body mass index was 28 kg/m2 (range: 18 to 53 kg/m2); 70% had baseline HCV RNA levels greater than 6 log10 IU/mL; 16% had cirrhosis; 49% had HCV genotype 3.
Ravitud osalejate (n = 278) vanuse mediaan oli 54 eluaastat (vahemikus 21...75); 54% osalejaist olid meessoost; 91% valgenahalised, 5% mustanahalised, 11% Hispaania või ladina päritolu; keskmine kehamassi indeks oli 28 kg/m2 (vahemikus 18...53 kg/m2); 70%-l oli ravieelne HCV RNA suurem kui 6 log10 RÜ/ml; 16%-l oli tsirroos; 49%-l oli HCV 3. genotüüp.
Treated subjects (n = 327) had a median age of 54 years (range: 19 to 70); 64% of the subjects were male; 79% were White; 17% were Black; 14% were Hispanic or Latino; mean body mass index was 29 kg/m2 (range: 18 to 56 kg/m2); 78% had baseline HCV RNA greater than 6 log10 IU/mL; 17% had cirrhosis; 89% had HCV genotype 1 and 11% had HCV genotype 4, 5 or 6.
Ravitud osalejate (n = 327) vanuse mediaan oli 54 eluaastat (vahemikus 19...70); 64% osalejaist olid meessoost; 79% valgenahalised, 17% mustanahalised, 14% Hispaania või ladina päritolu; keskmine kehamassi indeks oli 29 kg/m2 (vahemikus 18...56 kg/m2); 78%-l oli ravieelne HCV RNA suurem kui 6 log10 RÜ/ml; 17%-l oli tsirroos; 89%-l oli HCV 1. genotüüp ja 11 protsendil oli 4., 5. või genotüüp.
Treated subjects (n = 419) had a median age of 51 years (range: 19 to 74); 60% of the subjects were male; median body mass index was 25 kg/m2 (range: 17 to 44 kg/m2); the mean baseline HCV RNA level was 6.4 log10 IU/mL; 21% had cirrhosis; 78% had HCV genotype 3; 65% were prior relapsers.
Ravitud osalejate (n = 419) vanuse mediaan oli 51 eluaastat (vahemikus 19…74); 60% osalejaist olid meessoost; mediaan kehamassi indeks oli 25 kg/m2 (vahemikus 17…44 kg/m2); keskmine ravieelne HCV RNA oli 6,4 log10 RÜ/ml; 21%-l oli tsirroos; 78%-l oli HCV 3. genotüüp; 65%-l olid eelnevad retsidiivid.
Treated subjects (n = 499) had a median age of 50 years (range: 19 to 77); 66% of the subjects were male; 87% were White; 3% were Black; 14% were Hispanic or Latino; mean body mass index was 28 kg/m2 (range: 17 to 52 kg/m2); 57% had baseline HCV RNA levels greater than 6 log10 IU/mL; 20% had cirrhosis; 72% had HCV genotype 3.
Ravitud osalejate (n = 499) vanuse mediaan oli 50 eluaastat (vahemikus 19...77); 66% osalejaist olid meessoost; 87% valgenahalised, 3% mustanahalised, 14% Hispaania või ladina päritolu; keskmine kehamassi indeks oli 28 kg/m2 (vahemikus 17...52 kg/m2); 57%-l oli ravieelne HCV RNA suurem kui 6 log10 RÜ/ml; 20%-l oli tsirroos; 72%-l oli HCV 3. genotüüp.
Treated subjects (N=179) had a median age of 57 years (range: 26 to 70); 35.2% were prior pegIFN/RBV null responders; 28.5% were prior pegIFN/RBV partial responders, and 36.3% were prior pegIFN/RBV relapsers; 54.2% were male; 3.9% were Black; 12.8% had a history of depression or bipolar disorder; 87.7% had baseline HCV RNA levels of at least 800,000 IU/mL; 17.9% had portal fibrosis (F2) and 14.0% had bridging fibrosis (F3).
Ravitud patsientide (N = 394) mediaanvanus oli 54 eluaastat (vahemik 19…71 eluaastat); 49,0% patsientidest ei olnud reageerinud varasemale ravile pegIFN/RBV-ga, 21,8% olid reageerinud varasemale ravile pegIFN/RBV-ga osaliselt ja 29,2%-l oli tekkinud varasema pegIFN/RBV ravijärgne ägenemine; 57,6% olid mehed; 8,1% olid mustanahalised; 20,6%-l oli anamneesis depressioon või bipolaarne häire; 87,1%-l oli algtaseme HCV RNA sisaldus vähemalt 800 000 RÜ/ml; 17,8%-l oli fibroosiaste 2 (F2) ja 14,5%-l fibroosiaste 3 (F3); 58,4%-l oli HCV 1a genotüübi infektsioon ja 41,4%-l oli HCV 1b genotüübi infektsioon.
Treated subjects (N=305) had a median age of 54 years (range: 19 to 70); 65.2% were male; 11.8% were Black; 20.7% had a history of depression or bipolar disorder; 86.6% had baseline HCV RNA levels of at least 800,000 IU/mL; 18.4% had portal fibrosis (F2) and 17.7% had bridging fibrosis (F3).
Ravitud patsientide (N = 631) mediaanvanus oli 52 eluaastat (vahemik: 18…70 eluaastat); 54,5% olid mehed; 5,4% olid mustanahalised; 15,2%-l oli anamneesis depressioon või bipolaarne häire; 79,1%-l oli algtaseme HCV RNA sisaldus vähemalt 800 000 RÜ/ml; 15,4%-l oli fibroosiaste 2 (F2) ja 8,7%-l fibroosiaste 3 (F3); 67,7%-l oli HCV 1a genotüüp ja 32,3%-l oli HCV 1b genotüüp.
Treated subjects (N=380) had a median age of 58 years (range: 21 to 71); 42.1% were treatment-naïve, 36.1% were prior pegIFN/RBV null responders; 8.2% were prior pegIFN/RBV partial responders, 13.7% were prior pegIFN/RBV relapsers; 70.3% were male; 3.2% were Black; 14.7% had platelet counts of less than 90 x 109/L; 49.7% had albumin less than 40 g/L; 86.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 24.7% had a history of depression or bipolar disorder; 68.7% had HCV genotype 1a infection, 31.3% had HCV genotype 1b infection.
Ravitud patsientide (N = 179) mediaanvanus oli 57 eluaastat (vahemik 26…70 eluaastat); 35,2% patsientidest ei olnud reageerinud varasemale ravile pegIFN/RBV-ga, 28,5% olid reageerinud varasemale ravile pegIFN/RBV-ga osaliselt ja 36,3% oli tekkinud varasema pegIFN/RBV ravijärgne ägenemine; 54,2% olid mehed; 3,9% olid mustanahalised; 12,8%-l oli anamneesis depressioon või bipolaarne häire; 87,7% oli algtaseme HCV RNA sisaldus vähemalt 800 000 RÜ/ml; 17,9%-l oli fibroosiaste 2 (F2) ja 14,0%-l fibroosiaste 3 (F3).
Treated subjects (N=394) had a median age of 54 years (range: 19 to 71); 49.0% were prior pegIFN/RBV null responders; 21.8/% were prior pegIFN/RBV partial responders, and 29.2% were prior pegIFN/RBV relapsers; 57.6% were male; 8.1% were Black; 20.6% had a history of depression or bipolar disorder; 87.1% had baseline HCV RNA levels of at least 800,000 IU per mL; 17.8% had portal fibrosis (F2) and 14.5% had bridging fibrosis (F3); 58.4% had HCV genotype 1a infection; 41.4% had HCV genotype 1b infection.
Ravitud patsientide (N = 419) mediaanvanus oli 50 eluaastat (vahemik 19…70 eluaastat), 45,8% olid mehed; 4,8% olid mustanahalised; 9,3%-l oli anamneesis depressioon või bipolaarne häire; 73,3%-l oli algtaseme HCV RNA sisaldus vähemalt 800 000 RÜ/ml; 20,3%-l oli fibroosiaste 2 (F2) ja 10,0%-l oli fibroosiaste 3 (F3).
Treated subjects (N=394) had a median age of 54 years (range: 19 to 71); 49.0% were prior pegIFN/RBV null responders; 21.8/% were prior pegIFN/RBV partial responders; and 29.2% were prior pegIFN/RBV relapsers; 57.6% were male; 8.1% were Black; 19.8% had a body mass index of at least 30 kg/m2; 20.6% had a history of depression or bipolar disorder; 89.6% had IL28B non-CC genotype; 87.1% had baseline HCV RNA levels of at least 800,000 IU per mL; 17.8% had portal fibrosis (F2) and 14.5% had bridging fibrosis (F3); 58.4% had HCV genotype 1a infection; 41.4% had HCV genotype 1b infection.
Ravitud patsientide (N = 179) mediaanvanus oli 57 eluaastat (vahemik 26…70 eluaastat); 35,2% patsientidest ei olnud reageerinud varasemale ravile pegIFN/RBV-ga, 28,5% olid reageerinud varasemale ravile pegIFN/RBV-ga osaliselt ja 36,3% oli tekkinud varasema pegIFN/RBV ravijärgne ägenemine; 54,2% olid mehed; 3,9% olid mustanahalised; 21,8%-l kehamassiindeks oli vähemalt 30 kg/m2; 12,8%-l oli anamneesis depressioon või bipolaarne häire; 90,5%-l oli IL28B mitte-CC genotüüp; 87,7% oli algtaseme HCV RNA sisaldus vähemalt 800 000 RÜ/ml; 17,9%-l oli fibroosiaste 2 (F2) ja 14,0%-l fibroosiaste 3 (F3).
treated with a non-fibrin specific agent (primarily streptokinase).
Trombolüütikumiga ravitud patsientidest 84% said mitte-fibriin spetsiifilist ravimit (peamiselt streptokinaasi).
treated with roflumilast.
mitteravitud KOK-i haigete vahel.
treating
kõrvaltoimed
treating a fracture that is related to a disease such as Paget’s disease or cancer.
haigusega seotud (näiteks Pageti tõvest või vähist põhjustatud) luumurdude ravi.
Treating anaemia with related symptoms in adult cancer patients receiving chemotherapy
Aneemia ja sellega seotud sümptomite raviks vähktõvega täiskasvanutel, kes saavad keemiaravi.
Treating diarrhoea early is important (see section 4);
kui teil tekib kõhulahtisus – kõhulahtisuse varane ravi on oluline (vt lõik 4);
Treating flu:
Gripi ravi: annus
treating HIV infection
alternatiivsed ravimid HIV
Treating people donating their own blood before surgery.
Operatsioonieelselt oma verd andvate inimeste raviks.
Treating people donating their own blood before surgery.
Patsientide ravi operatsioonieelselt oma vere kogumiseks.
Treating symptomatic anaemia caused by chronic kidney disease (renal anaemia) in patients on dialysis, or not yet on dialysis.
Kroonilisest neerupuudulikkusest tingitud sümptomaatilise aneemia (renaalse aneemia) ravi dialüüsipatsientidel või patsientidel, kes ei saa veel dialüüsravi.
Treatme nt in patients with acute STEMI
Ägeda STEMI-ga patsientide ravi
Treatmen t in patients with acute STEMI
Ägeda STEMI-ga patsientide ravi
Treatmen t in patients with unstable angina and non- Q-wave MI
Ebastabiilse stenokardia ja Q-sakita müokardiinf arktiga patsientide ravi
treatment
alustamiseni
Treatment
Ravi erinevus
Treatment
Ravi:
Treatment
või
Treatment (LEVP 2006-1): The proportion of HAE attacks achieving unequivocal relief of the defining symptom within 4 hours after Cinryze treatment was comparable between the 22 children enrolled (age range: 2-17) and adults, with 89% and 86% of attacks achieving relief, respectively.
Ravi (LEVP 2006-1): päriliku angioödeemi hoogude osakaal, mille puhul määratlev sümptom selgelt leevendus 4 tunni jooksul pärast Cinryze-ravi, oli 22 kaasatud lapsel (vanusevahemik: 2–17) ja täiskasvanutel võrreldav, kuna leevenes vastavalt 89% ja 86% hoogudest.
Treatment - Invasive Aspergillosis Study 0041
Ravi – invasiivne aspergilloos Uuring 0041
treatment [chemotherapy +/- radiotherapy]
uuringuravile [keemiaravi +/- kiiritusravi]
Treatment adjustments
Ravi kohandamine
Treatment after LH surge but before LH peak
Ravi pärast LH tippväärtust
Treatment against Isospora should aim to minimize the shedding of oocysts into the environment, thereby reducing the risk for reinfection in groups/kennels with known and recurring Isospora infections.
Isospora vastase ravi eesmärk on vähendada ootsüstide eritumist keskkonda, et vähendada taasnakatumise riski gruppides/kennelites, kus on diagnoositud ja esinenud Isospora infektsioon.
Treatment and
Ravi ja tõrje:
Treatment and control of gastro-intestinal nematodes in pigs infected with:
Mao-sooletrakti ümarusstõbede ravi ja tõrje sigadel järgmiste infektsioonide korral:
treatment and DVT/PE
SVT/PE ravi ja SVT/PE
Treatment and metaphylaxis of porcine proliferative enteropathy (ileitis) caused by Lawsonia intracellularis.
Lawsonia intracellularis’e põhjustatud sigade proliferatiivse enteropaatia (ileiidi) ravi ja metafülaktika.
Treatment and metaphylaxis of swine dysentery in herds, caused by Brachyspira hyodysenteriae, where the disease has been diagnosed.
Brachyspira hyodysenteriae põhjustatud sigade düsenteeria ravi ja metafülaktika karjas, kus see haigus on diagnoositud.